SG11201807881VA - Compositions and methods for making antibodies based on use of an expression-enhancing locus - Google Patents
Compositions and methods for making antibodies based on use of an expression-enhancing locusInfo
- Publication number
- SG11201807881VA SG11201807881VA SG11201807881VA SG11201807881VA SG11201807881VA SG 11201807881V A SG11201807881V A SG 11201807881VA SG 11201807881V A SG11201807881V A SG 11201807881VA SG 11201807881V A SG11201807881V A SG 11201807881VA SG 11201807881V A SG11201807881V A SG 11201807881VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- expression
- rule
- tarrytown
- saw mill
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000699802 Cricetulus griseus Species 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028552 WO2017184831A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807881VA true SG11201807881VA (en) | 2018-10-30 |
Family
ID=58701850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807881VA SG11201807881VA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| SG10202010156XA SG10202010156XA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010156XA SG10202010156XA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11530277B2 (enExample) |
| EP (1) | EP3445780A1 (enExample) |
| JP (3) | JP7134868B2 (enExample) |
| KR (2) | KR102474757B1 (enExample) |
| CN (2) | CN109071633B (enExample) |
| AR (1) | AR108295A1 (enExample) |
| AU (2) | AU2017253240B2 (enExample) |
| BR (1) | BR112018071285A2 (enExample) |
| CA (1) | CA3015371A1 (enExample) |
| EA (1) | EA201892137A1 (enExample) |
| IL (2) | IL262268B2 (enExample) |
| MX (2) | MX2018012866A (enExample) |
| SG (2) | SG11201807881VA (enExample) |
| TW (1) | TW201803981A (enExample) |
| WO (1) | WO2017184831A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| WO2020034097A1 (en) | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| JP7208380B2 (ja) * | 2018-10-26 | 2023-01-18 | エフ．ホフマン－ラ ロシュ アーゲー | リコンビナーゼ媒介性カセット交換を使用した多重特異性抗体スクリーニング法 |
| CN113631711B (zh) * | 2018-12-21 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 核酸的靶向整合 |
| BR112021019368A2 (pt) * | 2019-03-29 | 2021-12-07 | Hoffmann La Roche | Método para produzir fcrn biotinilado no terminal c |
| AU2020252840B2 (en) | 2019-04-02 | 2025-01-23 | Chugai Seiyaku Kabushiki Kaisha | Method of introducing target-specific foreign gene |
| BR112021025401A2 (pt) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo trivalente, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante, composição e método para produzir uma célula de mamífero recombinante |
| WO2020254355A1 (en) | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| BR112021025436A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo biespecífico trivalente, biespecífico bivalente, biespecífico multivalente, para produzir uma célula de mamífero recombinante e para produzir um anticorpo trivalente, ácidos desoxirribonucleicos, usos de um ácido desoxirribonucleico, células de mamífero recombinante, composições e uso de mrna de recombinase cre |
| WO2020254357A1 (en) | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
| CA3140323A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| KR20220025806A (ko) * | 2019-06-26 | 2022-03-03 | 제넨테크, 인크. | 핵산의 무작위 구성 표적화 통합 |
| EP4087925A2 (en) * | 2020-01-10 | 2022-11-16 | F. Hoffmann-La Roche AG | Method for the assembly of large nucleic acids from short fragments |
| TW202342755A (zh) * | 2021-12-22 | 2023-11-01 | 美商建南德克公司 | 多載體重組酶介導的匣式交換 |
| TW202528546A (zh) | 2023-09-07 | 2025-07-16 | 美商再生元醫藥公司 | 經共價表面修飾之腺相關病毒的生產及純化 |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| US20250163468A1 (en) | 2023-11-21 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| WO2003101189A1 (en) | 2002-05-29 | 2003-12-11 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| JP2006512061A (ja) | 2002-11-14 | 2006-04-13 | ジェネンテック・インコーポレーテッド | イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法 |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| EP2115136A4 (en) | 2006-12-21 | 2010-05-19 | Glaxosmithkline Llc | NOVEL PROCEDURE |
| WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| ES2527173T3 (es) | 2009-06-02 | 2015-01-21 | Regeneron Pharmaceuticals, Inc. | Células de fucosilación deficiente |
| ES2865648T3 (es) | 2009-06-26 | 2021-10-15 | Regeneron Pharma | Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| FI3865581T3 (fi) | 2011-08-05 | 2024-11-02 | Regeneron Pharma | Humanisoituja universaaleja kevytketjun hiiriä |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI745610B (zh) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3209785B1 (en) * | 2014-10-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Novel cho integration sites and uses thereof |
| DK3353212T3 (da) | 2015-09-23 | 2021-12-20 | Regeneron Pharma | Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf |
-
2017
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko active Active
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 IL IL309065A patent/IL309065A/en unknown
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Ceased
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en not_active Ceased
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
-
2018
- 2018-10-19 MX MX2024014381A patent/MX2024014381A/es unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP7546015B2/ja active Active
-
2024
- 2024-08-26 JP JP2024144352A patent/JP7789143B2/ja active Active
- 2024-09-26 AU AU2024220126A patent/AU2024220126A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL262268B2 (en) | 2024-05-01 |
| KR102474757B1 (ko) | 2022-12-07 |
| AU2024220126A1 (en) | 2024-10-17 |
| EA201892137A1 (ru) | 2019-03-29 |
| CN109071633A (zh) | 2018-12-21 |
| CN109071633B (zh) | 2022-11-18 |
| JP2022164824A (ja) | 2022-10-27 |
| JP7134868B2 (ja) | 2022-09-12 |
| KR20210135340A (ko) | 2021-11-12 |
| AU2017253240B2 (en) | 2024-07-04 |
| EP3445780A1 (en) | 2019-02-27 |
| SG10202010156XA (en) | 2020-11-27 |
| WO2017184831A1 (en) | 2017-10-26 |
| KR20180134894A (ko) | 2018-12-19 |
| JP7789143B2 (ja) | 2025-12-19 |
| MX2024014381A (es) | 2024-12-06 |
| JP2024164196A (ja) | 2024-11-26 |
| IL262268B1 (en) | 2024-01-01 |
| JP2019514358A (ja) | 2019-06-06 |
| CA3015371A1 (en) | 2017-10-26 |
| US11530277B2 (en) | 2022-12-20 |
| MX2018012866A (es) | 2019-03-11 |
| TW201803981A (zh) | 2018-02-01 |
| IL262268A (en) | 2018-11-29 |
| US20190263937A1 (en) | 2019-08-29 |
| AU2017253240A1 (en) | 2018-09-20 |
| AR108295A1 (es) | 2018-08-08 |
| BR112018071285A2 (pt) | 2019-02-12 |
| JP7546015B2 (ja) | 2024-09-05 |
| IL309065A (en) | 2024-02-01 |
| US20230322956A1 (en) | 2023-10-12 |
| CN116004544A (zh) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201810331YA (en) | Single chain variable fragment cd3 binding proteins | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811270WA (en) | Systems and methods for trajectory determination | |
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201805792PA (en) | Chimeric proteins and methods of regulating gene expression | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201807794VA (en) | Naphthene-containing distillate stream compositions and uses thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201808398PA (en) | Cell line for recombinant protein and/or viral vector production |